MA37931A1 - Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite - Google Patents
Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduiteInfo
- Publication number
- MA37931A1 MA37931A1 MA37931A MA37931A MA37931A1 MA 37931 A1 MA37931 A1 MA 37931A1 MA 37931 A MA37931 A MA 37931A MA 37931 A MA37931 A MA 37931A MA 37931 A1 MA37931 A1 MA 37931A1
- Authority
- MA
- Morocco
- Prior art keywords
- treating cancer
- improved methods
- renal toxicity
- reduced renal
- cancer patient
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 231100000417 nephrotoxicity Toxicity 0.000 title 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2012/050630 WO2014027996A1 (en) | 2012-08-13 | 2012-08-13 | Improved methods for treating cancer with reduced renal toxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA37931A1 true MA37931A1 (fr) | 2016-07-29 |
Family
ID=50101360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37931A MA37931A1 (fr) | 2012-08-13 | 2012-08-12 | Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150258140A1 (enExample) |
| EP (1) | EP2882420A4 (enExample) |
| JP (1) | JP2015528446A (enExample) |
| CN (1) | CN104736143A (enExample) |
| AU (1) | AU2012387681A1 (enExample) |
| BR (1) | BR112015003111A2 (enExample) |
| CA (1) | CA2882156A1 (enExample) |
| EA (1) | EA201590325A1 (enExample) |
| IN (1) | IN2015KN00375A (enExample) |
| MA (1) | MA37931A1 (enExample) |
| SG (1) | SG11201501146VA (enExample) |
| WO (1) | WO2014027996A1 (enExample) |
| ZA (1) | ZA201501123B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2654484C1 (ru) * | 2012-05-11 | 2018-05-21 | Ресет Терапьютикс, Инк. | Карбазолсодержащие сульфонамиды в качестве модуляторов криптохрома |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04169532A (ja) * | 1990-11-01 | 1992-06-17 | Sumitomo Pharmaceut Co Ltd | 脂溶性白金錯体含有リポソーム製剤 |
| JPH04169531A (ja) * | 1990-11-01 | 1992-06-17 | Sumitomo Pharmaceut Co Ltd | 脂溶性白金錯体を含有するリポソーム製剤 |
| EP0551169A1 (en) * | 1992-01-10 | 1993-07-14 | Takeda Chemical Industries, Ltd. | Liposome composition and production thereof |
| EP0929293B1 (en) * | 1996-08-23 | 2003-10-22 | Sequus Pharmaceuticals, Inc. | Liposomes containing a cisplatin compound |
| DE19954613A1 (de) * | 1999-11-12 | 2001-05-17 | Enthone Omi Deutschland Gmbh | Verfahren zur stromlosen Verzinnung von Kupfer oder Kupferlegierungen |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| GR20060100144A (el) * | 2006-03-03 | 2007-10-17 | Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene | |
| EP2123258A1 (en) * | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
| US20120197060A1 (en) * | 2009-06-18 | 2012-08-02 | University Of Utah Research Foundation | Radiation enhanced macromolecular delivery of therapeutic agents for chemotherapy technology |
-
2012
- 2012-08-12 MA MA37931A patent/MA37931A1/fr unknown
- 2012-08-13 JP JP2015527429A patent/JP2015528446A/ja active Pending
- 2012-08-13 CN CN201280075225.2A patent/CN104736143A/zh active Pending
- 2012-08-13 BR BR112015003111A patent/BR112015003111A2/pt not_active IP Right Cessation
- 2012-08-13 CA CA2882156A patent/CA2882156A1/en not_active Abandoned
- 2012-08-13 SG SG11201501146VA patent/SG11201501146VA/en unknown
- 2012-08-13 WO PCT/US2012/050630 patent/WO2014027996A1/en not_active Ceased
- 2012-08-13 IN IN375KON2015 patent/IN2015KN00375A/en unknown
- 2012-08-13 EA EA201590325A patent/EA201590325A1/ru unknown
- 2012-08-13 US US14/421,392 patent/US20150258140A1/en not_active Abandoned
- 2012-08-13 AU AU2012387681A patent/AU2012387681A1/en not_active Abandoned
- 2012-08-13 EP EP12883054.4A patent/EP2882420A4/en not_active Withdrawn
-
2015
- 2015-02-18 ZA ZA2015/01123A patent/ZA201501123B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015003111A2 (pt) | 2017-10-10 |
| SG11201501146VA (en) | 2015-05-28 |
| CN104736143A (zh) | 2015-06-24 |
| JP2015528446A (ja) | 2015-09-28 |
| WO2014027996A1 (en) | 2014-02-20 |
| EP2882420A1 (en) | 2015-06-17 |
| EP2882420A4 (en) | 2016-06-01 |
| ZA201501123B (en) | 2020-02-26 |
| US20150258140A1 (en) | 2015-09-17 |
| CA2882156A1 (en) | 2014-02-20 |
| IN2015KN00375A (enExample) | 2015-07-10 |
| EA201590325A1 (ru) | 2015-09-30 |
| AU2012387681A1 (en) | 2015-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| EA201692271A1 (ru) | Терапевтически активные соединения и способы их применения | |
| HK1258570A1 (zh) | 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法 | |
| HK1251157A1 (zh) | 使用ACTRII配体陷阱治疗β-地中海贫血 | |
| EA200970953A1 (ru) | СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ | |
| WO2012159085A3 (en) | Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells | |
| WO2014145642A3 (en) | Nrf2 small molecule inhibitors for cancer therapy | |
| WO2018094190A3 (en) | Gut microbiota and treatment of cancer | |
| BR112016027048A8 (pt) | uso de um composto de fórmula i no tratamento de câncer cerebral e glioblastoma multiforme mgmt positivo | |
| WO2009111691A3 (en) | Combination therapy with c-met and egfr antagonists | |
| WO2017176628A8 (en) | Methods for solid tumor treatment | |
| WO2013052699A3 (en) | Novel quinoxaline inhibitors of pi3k | |
| WO2011133521A3 (en) | Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| BRPI0908635B8 (pt) | composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica | |
| BR112012029280A2 (pt) | variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão | |
| WO2012141796A3 (en) | Prostate cancer therapy with hsp90 inhibitory compounds | |
| EA201290517A1 (ru) | Гетероароматические арилтриазольные производные в качестве ингибиторов фермента pde10a | |
| JO3089B1 (ar) | مشتقات ايميدازول كمثبطات لانزيمات pde10a | |
| AU2013218357A8 (en) | Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors | |
| WO2011156811A3 (en) | Compounds for treatment of bovine mastitis | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| EA201992513A1 (ru) | Способ лечения рака груди | |
| HK1211203A1 (en) | Injectable cancer compositions | |
| MA37931A1 (fr) | Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite |